Rebound hypercalcemia after denosumab cessation during follow-up after surgical treatment for parathyroid carcinoma: case report and literature review

被引:0
|
作者
Schmitt, Lisa [1 ]
Theiler-Schwetz, Verena [1 ]
Sadoghi, Patrick [2 ]
Trummer, Christian [1 ]
Pilz, Stefan [1 ]
机构
[1] Med Univ Graz, Dept Internal Med, Div Endocrinol & Diabetol, Auenbruggerplatz 15, A-8036 Graz, Austria
[2] Med Univ Graz, Dept Orthopaed & Trauma, Graz, Austria
来源
ARCHIVES OF ENDOCRINOLOGY METABOLISM | 2024年 / 68卷
关键词
Hypercalcemia; denosumab; primary hyperparathyroidism; parathyroid carcinoma; rebound; GIANT-CELL TUMOR; DISCONTINUATION; MANAGEMENT; THERAPY;
D O I
10.20945/2359-4292-2024-0035
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Denosumab is a potent antiresorptive medication, commonly used in the treatment of osteoporosis, as well as in a variety of other diseases. Potential adverse rebound effects after its cessation include a loss in bone mineral density and an increased risk of osteoporotic fractures. Hypercalcemia is a less frequently reported rebound phenomenon after denosumab discontinuation, that may pose a diagnostic challenge to physicians as a rare non-parathyroid hormone (PTH) dependent cause of hypercalcemia. In our case, a 47-year-old male presented with rebound hypercalcemia after denosumab cessation during follow-up after surgical treatment for parathyroid carcinoma. This nonPTH-dependent hypercalcemia resolved after re-initiation of denosumab. We performed a systematic literature review on rebound hypercalcemia after denosumab cessation and identified 52 individual patient cases. Children appear to be more prone to developing rebound hypercalcemia, which could be attributed to their higher baseline bone turnover, underlying conditions, or denosumab dosage regimens. In most cases, patients initially presented with acute and often severe symptoms of hypercalcemia that occur from 1.75 to 9 months after denosumab cessation (4 to 9 months in adults). Most effective treatment approaches to sufficiently decrease serum calcium levels were bisphosphonates or re-administration of denosumab. A watch and wait strategy may be sufficient in asymptomatic cases, which are less common and probably underdiagnosed. Subsequent antiresorptive treatment after denosumab cessation, which is a common practice in osteoporosis treatment, may reduce the risk of rebound hypercalcemia. As denosumab is a frequently used drug in patients with advanced malignant diseases and rebound hypercalcemia with low PTH levels may raise the suspicion for skeletal metastases, awareness of this rebound effect may be for particular relevance in such settings.
引用
收藏
页数:11
相关论文
共 50 条
  • [1] Denosumab for the Treatment of Hypercalcemia in a Patient With Parathyroid Carcinoma: A Case Report
    Roukain, Abdallah
    Alwan, Heba
    Bongiovanni, Massimo
    Sykiotis, Gerasimos P.
    Kopp, Peter A.
    FRONTIERS IN ENDOCRINOLOGY, 2022, 12
  • [2] Long-term follow up after denosumab treatment for osteoporosis - rebound associated with hypercalcemia, parathyroid hyperplasia, severe bone mineral density loss, and multiple fractures: a case report
    Maugars, Yves
    Guillot, Pascale
    Glemarec, Joelle
    Berthelot, Jean-Marie
    Le Goff, Benoit
    Darrieutort-Laffite, Christelle
    JOURNAL OF MEDICAL CASE REPORTS, 2020, 14 (01)
  • [3] Metastatic parathyroid carcinoma diagnosed after five surgical attempts: a case report and review of the literature
    Mahboobipour, Amir Ali
    Pourabdollah, Mihan
    Hadaegh, Farzad
    Dizaji, Mohsen Herik
    Tavangar, Seyed Mohammad
    Shadmehr, Mohammad Behgam
    JOURNAL OF CARDIOTHORACIC SURGERY, 2024, 19 (01)
  • [4] Long-term follow up after denosumab treatment for osteoporosis – rebound associated with hypercalcemia, parathyroid hyperplasia, severe bone mineral density loss, and multiple fractures: a case report
    Yves Maugars
    Pascale Guillot
    Joëlle Glémarec
    Jean-Marie Berthelot
    Benoit Le Goff
    Christelle Darrieutort-Laffite
    Journal of Medical Case Reports, 14
  • [5] Long-Term Follow-Up after Conservative Surgical Treatment of Odontogenic Myxoma: A Case Report and Literature Review
    Sato, Hitoshi
    Kurihara, Yuji
    Shiogama, Sunao
    Saka, Kotaro
    Kurasawa, Yuya
    Itose, Masakatsu
    Yaso, Atsutoshi
    Shirota, Tatsuo
    CASE REPORTS IN DENTISTRY, 2019, 2019
  • [6] Hypercalcemia in metastatic parathyroid carcinoma followed by hypocalcemia after resection: A case report
    Ohashi, Takuya
    Kawago, Mitsumasa
    Hirai, Yoshimitsu
    Yata, Yumi
    Fusamoto, Aya
    Iguchi, Hideto
    Nakaya, Takahito
    Kiyoi, Megumi
    Miyasaka, Miwako
    Kawaji, Mari
    Furuta, Yuki
    Nishimura, Yoshiharu
    RESPIROLOGY CASE REPORTS, 2023, 11 (08):
  • [7] Follow-up after Ductal Carcinoma In Situ Treatment
    Gica, Nicolae
    Mustata, Laura Mihaela
    Peltecu, Gheorghe
    Panaitescu, Anca Maria
    CHIRURGIA, 2021, 116 (05) : S143 - S146
  • [8] Use of Denosumab for Renal Cell Carcinoma-Associated Malignant Hypercalcemia: A Case Report and Review of the Literature
    Freeman, Ashley
    El-Amm, Joelle
    Aragon-Ching, Jeanny B.
    CLINICAL GENITOURINARY CANCER, 2013, 11 (04) : E24 - E26
  • [9] A pituitary abscess with one year follow-up after conservative treatment: A case report
    Yuan, Ning
    Chai, Sanbao
    Sun, Jianbin
    Liu, Yufang
    Xin, Sixu
    Ji, Linong
    Zhang, Xiaomei
    NEUROENDOCRINOLOGY LETTERS, 2017, 38 (08) : 532 - 536
  • [10] Efficacy of follow-up after surgical treatment of colorectal liver metastases
    Langenhoff, B. S.
    Krabbe, P. F. M.
    Ruers, T. J. M.
    EJSO, 2009, 35 (02): : 180 - 186